<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
April 17, 1998
------------------------------------
Date of Report
(Date of Earliest Event Reported)
TAVA TECHNOLOGIES, INC.
--------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Colorado 0-19167 84-1042227
- ------------------------------- ----------- ----------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File No.) I. D. Number)
7887 E. Belleview Avenue, Suite 820, Englewood, Colorado 80111
- -------------------------------------------------------- ----------
(Address of principal executive offices) (zip code)
(303) 771-9794
----------------------------------------------------
(Registrant's telephone number, including area code)
<PAGE>
ITEM 5. OTHER EVENTS.
On April 17, 1998, the Company announced certain business developments
in a Press Release dated April 17, 1998, which is filed as Exhibit 20.1
hereto and incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(a) Not applicable.
(b) Not applicable.
(c) Exhibits. The following exhibit is filed with this Report:
20.1 Press Release dated April 17, 1998.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
TAVA Technologies, Inc.
Date: April 17, 1998 By: /s/ John Jenkins
----------------------------------
John Jenkins, President and CEO
<PAGE>
EXHIBIT 20.1
PRESS RELEASE
FOR IMMEDIATE RELEASE:
- ----------------------
APRIL 17, 1998
TAVA TECHNOLOGIES, INC. AND COLORADO MEDTECH, INC.
ANNOUNCE LICENSING AGREEMENT
Englewood, CO/ April 17, 1998/ TAVA Technologies (NASDAQ: TAVA) a leading
provider of automation and information technology solutions to industry,
today announced the signing of a licensing agreement with Colorado MEDtech,
Inc. (NASDAQ:CMED) for TAVA's Plant Y2kOne-TM- products for year 2000
compliance of biomedical devices used in hospitals, clinics, and extended
care facilities.
Colorado MEDtech will modify the Plant Y2kOne software tool and database
structure, as appropriate, to tailor it specifically to the needs of the
health care market. The modified system will be called BioMed Y2kOne-TM-.
Colorado MEDtech will offer a combination of tools and services to support
health care institutions' efforts to establish year 2000 compliance for their
biomedical devices.
Colorado MEDtech will work directly with clients, and in cooperation with
information technology service companies that are providing year 2000
compliance services in the health care industry. Colorado MEDtech will also
market TAVA's Plant Y2KOne-TM- product to hospitals, clinics, and extended
care facilities to address year 2000 compliance of embedded systems in
building operations systems such as HVAC controls, boilers, and sprinkler
systems.
John Jenkins, TAVA's CEO, said, "We believe that the market for year 2000
compliance tools and services in the health care industry is significant.
Health care providers need to be concerned about the compliance status of
their medical devices and their facility support systems. While Plant Y2K
<PAGE>
One-TM- will address the facility support systems, TAVA does not have
the expertise required to address medical device issues. Colorado MEDtech
brings that element to the table."
John Atanasoff, Colorado MEDtech's President and CEO, commented, "We believe
that, with our strong medical device background and the BioMed Y2kOne system
and database, we will be able to offer unique services to the health care
industry." Mr. Atanasoff also added that the company already has secured one
engagement to provide year 2000 compliance support for a large hospital chain.
Colorado MEDtech, Inc., a Boulder, Colorado-based medical products and
services company, through its wholly-owned affiliates and operating
divisions, is a leading full-service provider of advanced medical products
and comprehensive outsourcing services.
TAVA CEO John Jenkins provided the following brief general update.
"The Company's Y2k activity continues to grow. The company has hired more
than 70 staff since December 31, 1997, bringing current total headcount over
the 400 mark. Recent new accounts include, among others:
Chevron Corporation where TAVA is chartered to complete, by April 30th, the
inventory and assessment phase of a pilot project at Chevron's Richmond
California Business Unit; Johnson and Johnson who has begun using TAVA tools
and services at several of its global affiliates; Genencor; and Amgen.
The company's existing engagements continue to progress well and expand.
Among other developments: the company's Y2k work with Bristol-Myers Squibb
has moved from pilot stage to global rollout; Medeva Pharmaceuticals has
expanded TAVA's scope to cover all U.S. operations and is beginning early
remediation activity; and the company's work with Boeing has also expanded in
scope.
<PAGE>
The company's joint venture with R.W. Beck that addresses the utility market
also secured several engagements in its first two months of operation."
TAVA (www.tavatech.com) provides factory automation and control systems
integration helping clients in manufacturing and process industries integrate
their processes, applications, hardware and software into seamless
manufacturing enterprises. Located in 11 regional offices throughout the
U.S., TAVA has a staff of more than 400.
- --------------------------------------------------------------------------------
STATEMENTS MADE IN THIS PRESS RELEASE THAT ARE NOT HISTORICAL OR CURRENT
FACTS ARE "FORWARD LOOKING STATEMENTS" MADE PURSUANT TO THE SAFE HARBOR
PROVISIONS OF FEDERAL SECURITIES LAWS. FORWARD-LOOKING STATEMENTS REPRESENT
MANAGEMENT'S BEST JUDGMENT AS TO WHAT MAY OCCUR IN THE FUTURE, BUT ARE
SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS
AND EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED OR
PROJECTED. SUCH FACTORS INCLUDE ADVERSE ECONOMIC CONDITIONS, ENTRY OF NEW
AND STRONGER COMPETITORS, INADEQUATE CAPITAL, UNEXPECTED COSTS, FAILURE TO
INTEGRATE OPERATIONS OF RECENTLY ACQUIRED SUBSIDIARIES AND FAILURE TO
CAPITALIZE UPON ACCESS OF NEW CLIENTELE. SPECIFIC RISKS AND UNCERTAINTIES
WHICH MAY AFFECT FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY'S PLANT Y2K ONE
BUSINESS AND PROSPECTS INCLUDE THE POSSIBILITY THAT A COMPETITOR WILL DEVELOP
A MORE COMPREHENSIVE OR LESS EXPENSIVE Y2K SOLUTION, AND DELAYS IN MARKET
AWARENESS OF TAVA AND ITS PRODUCT AND SERVICE SOLUTIONS. THESE FACTORS AND
OTHERS ARE DISCUSSED IN THE "MANAGEMENT'S DISCUSSION AND ANALYSIS" SECTION OF
THE COMPANY'S ANNUAL REPORT ON FORM 10-KSB FOR THE FISCAL YEAR ENDED JUNE 30,
1997, TO WHICH REFERENCE SHOULD BE MADE.
###
CONTACTS:
TAVA Technologies, Inc. Pacific Consulting Group, Inc.
John Jenkins, CEO Scott Liolios
Telephone (303) 771-9794 Telephone (714) 574-3860
